

Foster Stockbroking Initiates Research Coverage on Medibio

Sydney, Australia – 11 November 2015: Medibio Limited (**MEB** or the **Company**) is pleased to announce that Australian stockbroking firm Foster Stockbroking has initiated research coverage on the Company.

The research report focuses on Medibio's three verticals for commercialization, the Corporate, Consumer and Medical markets.

The Foster Stockbroking research report can be read on the Company's website at www.medibio.com.au

Further Information:		Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885979	Medibio Media Enquiries to: Peter Taylor NWR Communications Peter@nwrcommunications.com.au T: +61 (0)412 036 231	

ABOUT MEDIBIO LIMITED

Medibio (ASX: MEB), is a medical technology company developing a new objective test to assist in the diagnosis of depression, other mental health disorders and chronic stress. This test utilizes circadian heart rate variability. The technology is based on the scientific finding that circadian heart rate variability is a sensitive measure for depression and other mental health disorders and chronic stress. The technology consists of a heart monitor that sends ECG recordings wirelessly to the cloud where a proprietary algorithms analyse and delivers a quantifiable measure which can be used by a clinician to assist in diagnosis. The Technology has the potential to be the first FDA Approved objective, evidence based approach to the diagnosis of depression and other mental health disorders. The technology has already benefited from 15 years of laboratory research and Medibio is undertaking a number of pivotal studies to validate its clinical utility. Medibio is not just a traditional Medical Device play with revenue dependent upon FDA certification. It has the only new and credible method for the diagnosis of stress and mental wellbeing which can be easily translated to the workplace stress/wellbeing market, wearable technology, and App market. This stress market can be accessed without regulatory approval. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.